Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

BCMA CARs in multiple myeloma: room for more?

Lydia Sarah Hui Lee, Kwee L. Yong

Blood (2021) 137 (21): 2859–2860.

https://doi.org/10.1182/blood.2021010833

Published: 2021

Journal Articles

Vial Sharing of Bortezomib Is Logistically Feasible and Significantly Reduces Drug Wastage and the Cost of Myeloma Treatment

Simon Cheesman, Aoife Shields, Raakhee Shah, Nisha Thakrar, Jeff Bradley, Tom Marler-Hausen, Shirley D'Sa, Charalampia Kyriakou, Atul Mehta, MD, Rakesh Popat, Neil Rabin, Ali Rismani, MBBS, Kwee L Yong, Ashu Wechalakar

Blood (2016) 128 (22): 5956.

https://doi.org/10.1182/blood.V128.22.5956.5956

Published: 2016

Journal Articles

Duration of Therapy Is Independently Associated with Improved Progression Free and Overall Survival Following First Line Therapy for Non-Transplant Eligible Patients with Multiple Myeloma: Retrospective Analysis from a Single Centre

Dunnya De-Silva, MBBS, Adam Bloomfield, Nicholas Counsell, Simon Cheesman, BPharm, Ali Rismani, MBBS, Neil Rabin, Shirley D'Sa, Charalampia Kyriakou, Jayne Galinsky, Sarah Richard, Rakesh Popat, Atul Mehta, MD, Kwee L Yong

Blood (2016) 128 (22): 5684.

https://doi.org/10.1182/blood.V128.22.5684.5684

Published: 2016

Journal Articles

RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based Therapy

Blood (2016) 128 (22): 3267.

https://doi.org/10.1182/blood.V128.22.3267.3267

Published: 2016

Journal Articles

Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience

Nicola Maciocia, MBChB, BSc, MRCP, Andrew Melville, MBBS, MA (Cantab), MRCP, Paul Michael Maciocia, BSc, MBBS, MRCP, Simon Cheesman, BPharm, Faye Sharpley, MBBChir, MA, MRCP, MSc, Karthik Ramasamy, MD PhD, Matthew Streetly, BMBS, MRCP, MRCPath, Matthew W Jenner, MD, Reuben Benjamin, MB, BS, FRCPath, Stephen A Schey, MD, Rakesh Popat, Shirley D'Sa, Ali Rismani, MBBS, Kwee L Yong, Neil Rabin

Blood (2016) 128 (22): 3312.

https://doi.org/10.1182/blood.V128.22.3312.3312

Published: 2016

Journal Articles

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Rakesh Popat, Sarah R Brown, Avie-Lee Tillotson, Fiona Collinson, Louise M Flanagan, Cathy D Williams, Kwee L Yong, Gordon Cook, MD PhD, Matthew W Jenner, MD, Martin Kaiser, Jim Cavet, FRCPath, Dima El-Sharkawi, MD, Chin-Hin Ng, MD MRCP, FRCPATH, Eric Low, Gareth J Morgan, MD PhD, Faith E Davies, MD

Blood (2016) 128 (22): 3321.

https://doi.org/10.1182/blood.V128.22.3321.3321

Published: 2016

Journal Articles

Clinical Outcomes of Phase I/II Clinical Trials for Patients with Relapsed/Refractory Haematological Malignancies: Experience of an Early Phase Clinical Trials Unit

Chin-Hin Ng, MD MRCP, FRCPATH, Dima El-Sharkawi, MD, Elspeth M Payne, MDPhD, Kwee L Yong, Kirit M Ardeshna, MD FRCP, FRCPATH, Asim Khwaja, FRCPath, Rakesh Popat

Blood (2016) 128 (22): 3613.

https://doi.org/10.1182/blood.V128.22.3613.3613

Published: 2016

Journal Articles

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

Selina J Chavda, MBBS BSc MRCP, Paul Michael Maciocia, BSc, MBBS, MRCP, Pavlina Mesiri, MSc, Nicholas Counsell, Jaimal Kothari, FRCPath, Antonia Bird, Ciaran Mariner, Anastasia Chew, MBBS, MRCP, FRCPATH, Katherine Clesham, MBBS, Sally Moore, BSc, FRPATH, FRCP, MBBS, Laura Percy, MBBS, MRCP, FRCPATH, Ali Rismani, MBBS, Shirley D'Sa, Rakesh Popat, Neil Rabin, Kwee L Yong

Blood (2016) 128 (22): 3465.

https://doi.org/10.1182/blood.V128.22.3465.3465

Published: 2016

Journal Articles

An APRIL Based Chimeric Antigen Receptor to Simultaneously Target BCMA and TACI in Multiple Myeloma (MM) Has Potent Activity in Vitro and in Vivo

Lydia Sarah Hui Lee, MBBS, MRCP, MRCPath, BSc, Benjamin Owen Draper, BSc, MSc, Neil Chaplin, BSc, MSc, Brian Philip, PhD, Melody Chin, BSc, MSc, Daria Galas-Filipowicz, BSc, MSc, Simon Thomas, PhD, Evangelia Kokalaki, BSc, MSc, James Francis, PhD, Kwee L Yong, Martin A Pule, MD PhD

Blood (2016) 128 (22): 379.

https://doi.org/10.1182/blood.V128.22.379.379

Published: 2016

Journal Articles

POEMS Syndrome: Demographics and Outcomes in a United Kingdom Cohort

David Foldes, Stephen Keddie, Stephanie Baldeweg, Mary Reilly, Kwee L Yong, Michael Lunn, Shirley D'Sa

Blood (2016) 128 (22): 5582.

https://doi.org/10.1182/blood.V128.22.5582.5582

Published: 2016

Journal Articles

Physical and Psychological Factors Influencing Fatigue and Quality of Life in Multiple Myeloma Survivors: Preliminary Results from the Mascot Lifestyle Study

Malgorzata Heinrich, PhD, Joanne Land, BSc, Orla McCourt, MSc, Stephanie Philpott, MSc, Bruce Paton, PhD, Rebecca J Beeken, PhD, Lee Smith, PhD, Dunnya De-Silva, MBBS, Ali Rismani, MBBS, Shirley D'Sa, Anastasia Chew, MBBS, MRCP, FRCPATH, Atul Mehta, MD, Abigail Fisher, PhD, Allan Hackshaw, PhD, Kwee L Yong

Blood (2016) 128 (22): 4776.

https://doi.org/10.1182/blood.V128.22.4776.4776

Published: 2016

Journal Articles

Prevalence of TP53 Mutations in Del(17p) Myeloma: Spectrum of Mutations and Effect on Survival

Melody Chin, BSc, MSc, Jonathan Sive, MBBS, Christopher Allen, BSc, Claire Roddie, MD PhD, Selina J Chavda, MBBS BSc MRCP, Dean Smith, MBBS, Rakesh Popat, Ali Rismani, MBBS, Shirley D'Sa, Neil Rabin, Rosemary E. Gale, PhD BSc, Kwee L Yong

Blood (2016) 128 (22): 4455.

https://doi.org/10.1182/blood.V128.22.4455.4455

Published: 2016

Journal Articles

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

Oliver C Cohen, MBBS MRCP, Neil Rabin, Nicholas Counsell, Roger G Owen, MD PhD, Bilyana Popova, Oliver Schofield, Janet Lyons-Lewis, Andy Rawstron, Christopher Spence, Ruth Mary de Tute, PhD FRCPath, Derralynn Hughes, MRCP, MRCPath, DPhil, MA, Sally Moore, BSc, FRPATH, FRCP, MBBS, Paul Smith, PhD, Kwee L Yong

Blood (2016) 128 (22): 4508.

https://doi.org/10.1182/blood.V128.22.4508.4508

Published: 2016

Journal Articles

Outcomes Following Salvage Autologous Stem Cell Transplant (ASCT2) Vs Low Dose Alkylating Consolidation Therapy Following Bortezomib-Containing Re-Induction for Relapsed Multiple Myeloma (MM) May be Dependent on Age and Symptomatic Status Initiation of Re-Induction: Results from the Myeloma X (Intensive) Trial

John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, David A Cairns, Cathy Williams, A Hockaday, J. D. Cavenagh, MD MRCP, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD

Blood (2015) 126 (23): 1981.

https://doi.org/10.1182/blood.V126.23.1981.1981

Published: 2015

Journal Articles

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Gordon Cook, MD PhD, Cathy Williams, David A Cairns, Anna Hockaday, Jamie Cavenagh, John A Snowden, MD FRCP, FRCPath, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, Guy Pratt, MD, Sally Chown, Earnest Heartin, Sheila J.M. O'Connor, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD

Blood (2015) 126 (23): 394.

https://doi.org/10.1182/blood.V126.23.394.394

Published: 2015

Journal Articles

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

Sam H Ahmedzai, MBChB BSc FRCP, John A Snowden, MD FRCP, FRCPath, Angela Cox, BA MA PhD, David A Cairns, Cathy D Williams, Anna Hockaday, Jamie Cavenagh, Christopher Parrish, MD, Kwee L Yong, MBChB, PhD, Jim Cavet, FRCPath, Hannah Hunter, Jennifer Bird, John Ashcroft, MD MBBChir, PhD MRCP, MA, FRCPath, Julia Brown, PhD, Curly Morris, MD, Gordon Cook, MD PhD

Blood (2015) 126 (23): 3180.

https://doi.org/10.1182/blood.V126.23.3180.3180

Published: 2015

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Kwee L Yong, MBChB, PhD, Sarah Brown, Samantha Hinsley, Louise Flanagan, Neil Rabin, MB,BS, PhD, Karthik Ramasamy, Jamie Cavenagh, Roger G Owen, Martin F Kaiser, MD, Eric Low, Catherine Williams

Blood (2015) 126 (23): 1840.

https://doi.org/10.1182/blood.V126.23.1840.1840

Published: 2015

Journal Articles

Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens

Arash Latifoltojar, MB BS, MSc, MPhil, Kwee L Yong, MBChB, PhD, Margaret Hall-Craggs, BA, MB BS, MD, Neil Rabin, MB,BS, PhD, Rakesh Popat, MBBS, PhD, Alan Bainbridge, Magdalena Sokolska, Nikolaos Dikaios, Shirley D'Sa, MD FRCP, FRCPath, Ali Rismani, MBBS, Shonit Punwani, Mb BS, BSc, PhD

Blood (2015) 126 (23): 1850.

https://doi.org/10.1182/blood.V126.23.1850.1850

Published: 2015

Journal Articles

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial

Rakesh Popat, MBBS, PhD, Sarah R Brown, Louise M Flanagan, Andrew Hall, Bhuvan Kishore, MBBS, FRPATH, MRCP, Matthew Streetly, Heather E Oakervee, Simon L. Hallam, Matthew Smith, MBBS, MA, MRCP, MRCPath, MD, Kwee L Yong, MBChB, PhD, Gordon Cook, MD PhD, James D. Cavenagh, MD

Blood (2015) 126 (23): 1826.

https://doi.org/10.1182/blood.V126.23.1826.1826

Published: 2015

Journal Articles

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

Blood (2014) 124 (21): 4745.

https://doi.org/10.1182/blood.V124.21.4745.4745

Published: 2014

NARROW

BCMA CARs in multiple myeloma: room for more?

Vial Sharing of Bortezomib Is Logistically Feasible and Significantly Reduces Drug Wastage and the Cost of Myeloma Treatment

Duration of Therapy Is Independently Associated with Improved Progression Free and Overall Survival Following First Line Therapy for Non-Transplant Eligible Patients with Multiple Myeloma: Retrospective Analysis from a Single Centre

RNA Sequencing of Newly Diagnosed Multiple Myeloma to Identify a Predictive Signature for Proteasome Inhibitor-Based Therapy

Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience

A Phase I Dose-Escalation Study of the Class 1 Selective Histone Deacetylase Inhibitor CHR-3996 in Combination with Tosedostat for Patients with Relapsed, Refractory Multiple Myeloma: Results of the Muk Three Trial

Clinical Outcomes of Phase I/II Clinical Trials for Patients with Relapsed/Refractory Haematological Malignancies: Experience of an Early Phase Clinical Trials Unit

Factors Influencing Outcomes of Relapse from Front-Line Autologous Stem Cell Transplant (ASCT) over a 14 Year Period: A Single Centre Experience

An APRIL Based Chimeric Antigen Receptor to Simultaneously Target BCMA and TACI in Multiple Myeloma (MM) Has Potent Activity in Vitro and in Vivo

POEMS Syndrome: Demographics and Outcomes in a United Kingdom Cohort

Physical and Psychological Factors Influencing Fatigue and Quality of Life in Multiple Myeloma Survivors: Preliminary Results from the Mascot Lifestyle Study

Prevalence of TP53 Mutations in Del(17p) Myeloma: Spectrum of Mutations and Effect on Survival

Bortezomib Consolidation Following Upfront ASCT for Multiple Myeloma Deepens Disease Response and MRD-Negative Rate without Compromising Response to Subsequent Bortezomib Salvage: Results of a Phase II Study

A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial

Patient-Reported Outcomes (PRO) in the Setting of Relapsed Myeloma: The Influence of Treatment Strategies and Genetic Variants Predict Quality of Life and Pain Experience

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Whole Body (WB) MRI in Newly Diagnosed Multiple Myeloma (MM): Fat Fraction Changes at 8 Weeks Predict Response to Induction with Bortezomib Regimens

Bortezomib (Velcade), Thalidomide, Dexamethasone and Panobinostat (VTD-P) Is a Safe, Well Tolerated and Efficacious Regimen for Patients with Relapsed Multiple Myeloma: Preliminary Results of the Muk-Six Trial

Subcutaneous PAD As Induction Therapy for Patients with Newly Diagnosed Myeloma: A Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Patients with Deferred Autologous Stem Cell Transplantation (PADIMAC)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only